"This study underscores the importance of standardizing dosing instructions, which CHPA has long supported as a way of helping parents to appropriately treat their children’s symptoms with over-the-counter
Epilepsy is one of the most common neurological diseases, affecting 70 million worldwide and up to 5 million people in Latin America – and the successful treatment of
The FDA Office of Drug Evaluation III responded to the Company’s formal appeal filed in response to the Complete Response Letter (CRL) of July 27, 2012 to the
On June 25, 2014, Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principle goals; 1) initiating studies utilizing Ampligen as a potential adjuvant enhancement of Bioclones’
In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer’s disease, after 52 weeks of treatment.
Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic
The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting two inflammatory mediators, proteins which play a key role in major autoimmune diseases. "This is
Qudexy XR and Topiramate Extended-Release Capsules are indicated as initial monotherapy in patients 10 years of age and older with partial-onset seizures (POS) or primary generalized tonic-clonic seizures.
The study is on track with Genticel’s initial projections. All of the 39 investigation sites across seven European countries (Belgium, Finland, France, Germany, the Netherlands, Spain and the
HinsBet is a new type of prandial insulin, developed using the Company’s proprietary BioChaperone technology, that has been designed to reconcile the performance of insulin analogs with the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.